AR101051A1 - Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos - Google Patents

Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos

Info

Publication number
AR101051A1
AR101051A1 ARP140102236A ARP140102236A AR101051A1 AR 101051 A1 AR101051 A1 AR 101051A1 AR P140102236 A ARP140102236 A AR P140102236A AR P140102236 A ARP140102236 A AR P140102236A AR 101051 A1 AR101051 A1 AR 101051A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
alkoxy
hydroxy
halogen
Prior art date
Application number
ARP140102236A
Other languages
English (en)
Inventor
Tiainen Eija
Visnen Emilia
Haikarainen Anssi
Pietikinen Pekka
Passiniemi Mikko
Karjalainen Arja
Rummakko Petteri
Wohlfahrt Gerd
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR101051A1 publication Critical patent/AR101051A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) donde los átomos del anillo Z¹ y Z² son, en forma independiente, C o N con la condición de que al menos uno de los átomos del anillo Z¹ y Z² es C; A es un anillo carbocíclico de 3 - 7 miembros no aromático o heterocíclico de 5 - 6 miembros no aromático; B es un anillo heterocíclico de 5 - 6 miembros, o, en los casos donde A es un anillo carbocíclico de 3 - 7 miembros no aromático, B también puede ser un anillo heterocíclico de 7 - 12 miembros; R¹ es halógeno, CHF₂, CF₃ o C₁₋₇ alquilo; R² es ciano o nitro; R³ es H, halógeno o C₁₋₇ alquilo; R⁴ es C₁₋₇ alquilo, C₂₋₇ alquenilo, C₃₋₇ cicloalquilo, C₃₋₇ cicloalquil-C₁₋₇ alquilo, hidroxi-C₁₋₇ alquilo, halo-C₁₋₇ alquilo, C₁₋₇ alcoxi-C₁₋₇ alquilo, C₁₋₇ alquilcarbonilo o fenil-C₁₋₇ alquilo; R⁵ es H, OH, C₁₋₇ alquilo, C₁₋₇ alcoxi o hidroxi-C₁₋₇ alquilo; R⁵, R⁶ y R⁶ son, en forma independiente, H, OH, C₁₋₇ alquilo o halógeno; o, en los casos donde R⁶ y R⁶ se unen al mismo átomo de carbono del anillo, R⁶ y R⁶ pueden formar, junto con el átomo de carbono al que se unen, un anillo C₃₋₇ cicloalquilo; R⁷ es H, OH, ciano, halógeno, C₁₋₇ alquilo, C₃₋₇ cicloalquilo, C₁₋₇ alcoxi, hidroxi-C₁₋₇ alquilo, halo-C₁₋₇ alquilo, ciano-C₁₋₇ alquilo, halo-C₁₋₇ alcoxi, C₁₋₇ alcoxi-C₁₋₇ alquilo, hidroxi-C₁₋₇ alcoxi-C₁₋₇ alquilo, C₁₋₇ alquilcarbonil-C₁₋₇ alquilo o -C₁₋₇ alquil-X-(CH₂)ₙ-R⁹; R⁸ es H o C₁₋₇ alquilo; R⁹ es un anillo carbocíclico de 3 - 7 miembros opcionalmente sustituido, un anillo heterocíclico de 4 - 6 miembros opcionalmente sustituido, o -NR¹⁰R¹¹; X es una unión, oxígeno o -NH-; n = 0 - 3; R¹⁰ y R¹¹ son, en forma independiente, H, C₁₋₇ alquilo o C₁₋₇ alquilcarbonilo; o una sal aceptable farmacéuticamente del mismo.
ARP140102236A 2013-06-11 2014-06-10 Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos AR101051A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833846P 2013-06-11 2013-06-11

Publications (1)

Publication Number Publication Date
AR101051A1 true AR101051A1 (es) 2016-11-23

Family

ID=51062835

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102236A AR101051A1 (es) 2013-06-11 2014-06-10 Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos

Country Status (21)

Country Link
US (1) US9890139B2 (es)
EP (1) EP3008042A1 (es)
JP (1) JP6356790B2 (es)
KR (1) KR20160019928A (es)
CN (1) CN105339355B (es)
AR (1) AR101051A1 (es)
AU (1) AU2014283150B2 (es)
CA (1) CA2912166A1 (es)
CL (1) CL2015003595A1 (es)
EA (1) EA029280B1 (es)
HK (1) HK1220690A1 (es)
MA (1) MA38645B1 (es)
MX (1) MX2015016943A (es)
PE (1) PE20160050A1 (es)
PH (1) PH12015502723B1 (es)
SA (1) SA515370266B1 (es)
SG (1) SG11201509449XA (es)
TW (1) TW201534586A (es)
UA (1) UA116808C2 (es)
WO (1) WO2014202827A1 (es)
ZA (1) ZA201508398B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
TWI692679B (zh) * 2017-12-22 2020-05-01 美商慧盛材料美國責任有限公司 光阻剝除劑
CN108586443B (zh) * 2018-01-31 2019-11-26 佳木斯大学附属第一医院 一种防治支气管肺癌的药物及其制备方法
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
WO2023091726A1 (en) * 2021-11-18 2023-05-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin‑dependent kinase 12 (cdk12)
CN114369030A (zh) * 2022-01-14 2022-04-19 浙江大学衢州研究院 一种2,2,4,4-四甲基-1,3-环丁二胺的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546194A (en) 1984-05-29 1985-10-08 G. D. Searle & Co. Substituted chromanon-2-yl alkanols and derivatives thereof
EP0301751B1 (en) 1987-07-31 1993-03-10 Takeda Chemical Industries, Ltd. Pyridinium derivatives, their production and use
WO2001046199A1 (en) 1999-12-22 2001-06-28 Eli Lilly And Company Methods and compounds for inhibiting mrp1
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
WO2005075426A1 (en) 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
JP2008515998A (ja) 2004-10-13 2008-05-15 スミスクライン ビーチャム コーポレーション 化合物
AP2007004026A0 (en) 2004-12-21 2007-06-30 Pfizer Prod Inc Macrolides
AP2358A (en) 2005-05-09 2012-01-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use.
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
US20100216813A1 (en) * 2005-11-30 2010-08-26 Smithkline Beecham Corporation Pyrrolidineanilines
DE602007007734D1 (de) * 2006-02-10 2010-08-26 Janssen Pharmaceutica Nv Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
WO2007099385A1 (en) 2006-03-01 2007-09-07 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase iv inhibitor compounds and compositions
KR20090035695A (ko) * 2006-08-09 2009-04-10 스미스클라인 비참 코포레이션 프로게스테론 수용체 조정인자로서의 피롤리디논 아닐린
WO2008077089A1 (en) 2006-12-19 2008-06-26 Smithkline Beecham Corporation Pyrrolidinanilines
WO2008086131A1 (en) 2007-01-12 2008-07-17 Allergan, Inc. Naphthylmethylimidizoles as therapeutic agents
WO2009124882A1 (en) 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
JO2892B1 (en) * 2009-06-26 2015-09-15 نوفارتيس ايه جي CYP inhibitors 17
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2598481B1 (en) 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
CA2808543C (en) * 2010-08-20 2016-01-26 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
CN102372717B (zh) * 2010-08-20 2014-06-18 和记黄埔医药（上海）有限公司 吡咯并嘧啶类化合物及其用途
EP2685981B1 (en) 2011-03-17 2016-08-24 Bristol-Myers Squibb Company Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
EP2882733B1 (en) * 2012-08-08 2017-04-26 Novartis Tiergesundheit AG Substituted azines as pesticides

Also Published As

Publication number Publication date
US20160130254A1 (en) 2016-05-12
ZA201508398B (en) 2017-06-28
JP2016523851A (ja) 2016-08-12
MX2015016943A (es) 2016-04-25
EA201592294A1 (ru) 2016-05-31
AU2014283150A1 (en) 2015-12-03
PH12015502723A1 (en) 2016-03-14
UA116808C2 (uk) 2018-05-10
CA2912166A1 (en) 2014-12-24
SG11201509449XA (en) 2015-12-30
MA38645B1 (fr) 2018-11-30
WO2014202827A1 (en) 2014-12-24
HK1220690A1 (zh) 2017-05-12
AU2014283150B2 (en) 2018-05-10
CN105339355A (zh) 2016-02-17
CN105339355B (zh) 2018-02-27
TW201534586A (zh) 2015-09-16
EA029280B1 (ru) 2018-03-30
CL2015003595A1 (es) 2016-07-08
PH12015502723B1 (en) 2016-03-14
SA515370266B1 (ar) 2018-04-15
MA38645A1 (fr) 2018-05-31
EP3008042A1 (en) 2016-04-20
US9890139B2 (en) 2018-02-13
JP6356790B2 (ja) 2018-07-11
KR20160019928A (ko) 2016-02-22
PE20160050A1 (es) 2016-02-18

Similar Documents

Publication Publication Date Title
AR101051A1 (es) Compuestos no esteroideos inhibidores de cyp17 / antiandrógenos
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR096684A1 (es) Compuestos para tratar atrofia muscular espinal
AR112797A1 (es) Inhibidores de kras g12c y métodos para utilizarlos
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
AR097866A1 (es) Derivados de 4-azaindol
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103828A1 (es) INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR117139A1 (es) Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl)
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
ES2662444T3 (es) Derivado de piridina
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
CR20120643A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR106138A1 (es) Compuestos y métodos para inhibir jak
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR104878A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR100439A1 (es) Derivados de carboxamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure